Heska Corporation has licensed gene delivery and DNA manufacturing technology from Valentis, Inc. The technology will be used by Heska to complete development of a novel gene medicine for the treatment of canine cancer. Specific terms of the agreement, which include an up-front license fee, milestone payments and a royalty, were not disclosed. Dr. Dan Read more about Heska Licenses Valentis Gene Delivery Technology[…]